Fitch maintains Bristol-Myers Squibb's (BMY) debt rating at A+ and its outlook at Negative...


Fitch maintains Bristol-Myers Squibb's (BMY) debt rating at A+ and its outlook at Negative following the drug company's deal to buy Inhibitex (INHX) for $2.5B. While Bristol has enough cash to pay for Inhibitex, the latter won't provide immediate relief to an expected fall in Bristol's revenues because of the expiration of patents.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs